Abbott Q4 2025: EPS Keeps Rising, 2026 Roadmap Puts a Higher Bar on ABT

What Abbott reported for Q4 2025 and the full year

Abbott Laboratories (ABT) closed out 2025 with a fourth-quarter GAAP diluted earnings per share (EPS) of $1.01 and an adjusted EPS of $1.50, up 12% from a year earlier. The press release frames this as a margin-friendly finish rather than a one-off blip, a distinction that matters when you’re juggling a portfolio that stretches from heart devices to diagnostics. For the full year, Abbott posted sales of about $44.3 billion, up 5.7% on a reported basis and 5.5% on an organic basis, with 6.7% growth when COVID-19 testing-related sales are excluded. The numbers are not a single bell chime but a pattern: the core business is carrying the load while the COVID-era comp is fading into the background.

Fourth-quarter results show the same rhythm: Q4 sales rose 4.4% on a reported basis, with 3.0% organic growth and 3.8% when you strip out COVID-related testing. The company stresses that momentum is broad-based, and the gross-to-operating margin narrative underpins the EPS acceleration in the back half of the year. In short, the last three months looked like a clean sprint rather than a stoic plod through a rocky quarter.

Beyond the headline numbers, Abbott’s 2025 footprint earned its keep: GAAP diluted EPS of $3.72 for the year and adjusted diluted EPS of $5.15, reflecting roughly 10% growth at the midpoint of the year’s results. The revenue backdrop—more growth in the core portfolio, tempered by the unwinding of COVID-19 testing demand—creates a credible base for the 2026 outlook without pretending the wind is always at your back.

2026 guidance and what it means for EPS and the revenue forecast

Abbott laid out a 2026 organic sales growth target of 6.5% to 7.5%, a pace that could reaccelerate the top line even as the company continues to cycle through new product approvals and strategic investments. On the earnings side, the company guided for full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which implies about 10% growth at the midpoint relative to 2025. That framing is meaningful because it pairs a robust top-line target with a disciplined margin and cost-control narrative, a combination investors typically reward when it is executed with credible product launches and regulatory progress.

Put differently, the 2026 “revenue forecast” is designed to support a higher EPS floor while still preserving flexibility to absorb unexpected headwinds or capitalize on growth opportunities. In earnings terminology, the guidance sits in a zone where “EPS consensus” for a number like $5.60-something might be nudged higher if the company hits the midpoint of its range, or held steady if results land closer to either boundary. In plain English: the guidance is the plan, and the plan is made to be tested by execution.

Strategic moves and near-term catalysts you should watch

• M&A and diagnostics: Abbott announced an agreement in November to acquire Exact Sciences, a move designed to position the company to lead in cancer diagnostics. The strategic rationale is straightforward—expand the diagnostic footprint and cross-sell into a broader portfolio. The integration risks and regulatory timing will be a tell on follow-up quarters and how quickly the expected uplift in earnings emerges.
• Regulatory and product milestones in electrophysiology: Abbott’s leadership in electrophysiology advanced with regulatory approvals—most notably the FDA clearance for the Volt PFA System in December and the CE Mark for the TactiFlex Duo Ablation Catheter in January. These approvals are not mere press-release fodder; they can shift product mix and pricing power if adoption metrics move favorably.
• Pipeline momentum: The company highlighted additional regulatory and market milestones in early 2026, signaling a continued cadence of launches and approvals across its portfolio. If these milestones translate into recalled revenue streams and expanded addressable markets, the 6.5–7.5% organic growth target starts to look less aspirational and more probable.

What this might portend for Abbott and its peers

Matt Levine would pose the question with a half-smile: what does a company do when it blends a mature portfolio with a near-term growth itch? Abbott’s 2025 finish line shows a business that has learned to live with a wide range of demand signals—from high-margin device sales to diagnostics life cycles—without letting any one leg fail. The 2026 guidance tightens the leverage on confidence: a 6.5–7.5% organic top-line climb paired with a 10% mid-point EPS uplift suggests management believes it can compound earnings even when some markets look structurally mature.

From a sector perspective, this is a signal that diagnostics and electrophysiology remain high-priority growth vectors. The Exact Sciences deal adds a bet on precision oncology that could create a more resilient earnings stream if Medicare, private payers, and adoption curves align. For peers, the message is clear: invest in clinically meaningful innovations, maintain a disciplined cost structure, and be prepared to integrate acquisitions in a way that can show up in both EPS and organic growth metrics over a multi-year horizon.

Analysts will weigh Abbott's “earnings surprise” potential against evolving interest rates, supply chain dynamics, and competitive density in diagnostics. The company’s ability to preserve operating leverage while absorbing a large acquisition and bringing new products to market will be a focal point. If the 2026 revenue forecast and EPS path hold, ABT could become a reference case for a single diversified health-care conglomerate that signals growth through the product cycle rather than through a single new blockbuster.

Conclusion: a measured step toward a steadier growth profile

Abbott’s 2025 results reinforce the notion that a diversified portfolio can generate steady EPS growth even as the COVID-era boost fades. The 2026 plan threads a careful needle: maintain margin discipline, push core growth to a mid-to-high single-digit pace, and deploy capital into diagnostics and electrophysiology with the expectation of meaningful leverage. The presence of an Exact Sciences deal adds optionality, while the regulatory milestones in Volt PFA and TactiFlex suggest near-term tailwinds in high-growth segments.

For readers tracking ABT, EPS, and the broader sector, the takeaway is not a fireworks display but a calibrated forecast. If the EPS consensus for 2026 edges higher as the company approaches the midpoint of its guide, you could see a constructive re-pricing of Abbott’s growth profile—an outcome that makes the risk-and-reward math of health care conglomerates a bit more interesting in 2026 than in the recent past.